Navigation Links
100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeich's Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
Date:8/23/2010

100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeich's Genous™ Bio-engineered... -- SENDAI, Japan, Aug. 23 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Surveys, Polls and Research Click to view news release full screen  

100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeich's Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient

   

First Report of Early In Vivo Findings Presented as Part of Symposium at the Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics

SENDAI, Japan, Aug. 23 /PRNewswire/ -- OrbusNeich today reported that optical coherence tomography (OCT) evaluation of a patient with anterior ST-elevation myocardial infarction (STEMI) who received two of the company's Genous Bio-engineered R stents showed 100 percent coverage of the stent struts and complete neointimal coverage 26 days post-implantation.

Stephen Wai-Luen Lee, M.B.B.S., of the Queen Mary Hospital in Hong Kong presented the findings in a presentation, "Genous Combo – The Latest of Novel Devices in the Evolution of the Coronary Intervention," as part of a symposium at the Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics.

Following a diagnosis of acute thrombotic occlusion of the proximal left anterior descending artery (LAD), with critical lesions identified in the proximal and mid LAD and a chronic total occlusion (CTO) of the proximal right coronary artery (RCA), the patient, a 62-year-old male, received two 2.5 mm diameter Genous Bio-engineered R stents. The proximal stent was 23 mm in length, and the distal stent was 13 mm in length.  At 26 days post-implantation, physicians conducted an OCT assessment when a staged procedure was performed to the CTO on the RCA with implantation of an additional 2.5 mm diameter by 23 mm length Genous Bio-engineered R stent.

"This is the first documentation of complete endothelialization after 26 days of Genous stent implantation, showing the pro-healing effect in vivo," said Prof. Lee.

About Genous  Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeichOrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, SafeCut™, Sapphire™, Sapphire NC, Avita™, Avita HP and Lumina™. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.


'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
2. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
3. Cardinal Health Raises Quarterly Dividend By 11 Percent
4. New Study Shows 84 Percent Reduction in Post-Cesarean Section Infections Through Comprehensive Prevention Strategy
5. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
6. Volcano Reports 44 Percent Increase in Fourth Quarter Revenues
7. HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures
8. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
9. Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors
10. Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market
11. $232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
Breaking Medicine News(10 mins):